Cambridge, UK, 13 July 2017 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to announce that it was voted as the winner of the Summer 2017 BioNewsRound Award at the One Nucleus event held ahead of the Annual On Helix conference in Cambridge.
Microbiotica won the award based on the prospects for the company, its reflection on innovation in the UK sector and its potential to bring benefits to patients. Microbiotica was launched at the end of 2016 as the newest spin-out company from the UK’s world-renowned Wellcome Trust Sanger Institute with £8m funding from Cambridge Innovation Capital and IP Group. Each of 10 companies shortlisted for the Award presented to the audience which voted for their choice.
Mike Romanos, CEO of Microbiotica, said: “As a relatively new company it’s encouraging that our potential is already being recognised. Microbiotica was formed on world-class human microbiome research and we are looking forward to driving forward the discovery and development of novel microbiome-based therapeutics and biomarkers using this science.”
Harriet Fear, CEO of One Nucleus, said: “Choosing the 10 finalists from the many entries was tough. It was interesting that three of the finalists were in the microbiome space, reflecting the growing interest and huge potential in the area. Microbiotica was a worthy winner and it was great that they were presented with the award at our event held on the Wellcome Trust Genome Campus."